» Articles » PMID: 34885024

Review: Challenges of In Vitro CAF Modelling in Liver Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 10
PMID 34885024
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Primary and secondary liver cancer are the third cause of death in the world, and as the incidence is increasing, liver cancer represents a global health burden. Current treatment strategies are insufficient to permanently cure patients from this devastating disease, and therefore other approaches are under investigation. The importance of cancer-associated fibroblasts (CAFs) in the tumour microenvironment is evident, and many pre-clinical studies have shown increased tumour aggressiveness in the presence of CAFs. However, it remains unclear how hepatic stellate cells are triggered by the tumour to become CAFs and how the recently described CAF subtypes originate and orchestrate pro-tumoural effects. Specialized in vitro systems will be needed to address these questions. In this review, we present the currently used in vitro models to study CAFs in primary and secondary liver cancer and highlight the trend from using oversimplified 2D culture systems to more complex 3D models. Relatively few studies report on the impact of cancer (sub)types on CAFs and the tumour microenvironment, and most studies investigated the impact of secreted factors due to the nature of the models.

Citing Articles

Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential.

Milosevic V, Ostman A Ups J Med Sci. 2024; 129.

PMID: 38863724 PMC: 11165253. DOI: 10.48101/ujms.v129.10710.


Prediction of CAF-related genes in immunotherapy and drug sensitivity in hepatocellular carcinoma: a multi-database analysis.

Yao Y, Yang K, Wang Q, Zhu Z, Li S, Li B Genes Immun. 2024; 25(1):55-65.

PMID: 38233508 PMC: 10873201. DOI: 10.1038/s41435-024-00252-z.


vascularized immunocompetent patient-derived model to test cancer therapies.

Le H, Deforges J, Hua G, Idoux-Gillet Y, Ponte C, Lindner V iScience. 2023; 26(10):108094.

PMID: 37860774 PMC: 10582498. DOI: 10.1016/j.isci.2023.108094.

References
1.
Raza A, Sood G . Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014; 20(15):4115-27. PMC: 3989948. DOI: 10.3748/wjg.v20.i15.4115. View

2.
Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y . Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int. 2014; 2014:764981. PMC: 4095710. DOI: 10.1155/2014/764981. View

3.
Liu J, Li P, Wang L, Li M, Ge Z, Noordam L . Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cell Mol Gastroenterol Hepatol. 2020; 11(2):407-431. PMC: 7788239. DOI: 10.1016/j.jcmgh.2020.09.003. View

4.
Mueller L, von Seggern L, Schumacher J, Goumas F, Wilms C, Braun F . TNF-alpha similarly induces IL-6 and MCP-1 in fibroblasts from colorectal liver metastases and normal liver fibroblasts. Biochem Biophys Res Commun. 2010; 397(3):586-91. DOI: 10.1016/j.bbrc.2010.05.163. View

5.
Yamaguchi H, Kuroda K, Sugitani M, Takayama T, Hasegawa K, Esumi M . Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. Int J Oncol. 2017; 50(5):1749-1759. DOI: 10.3892/ijo.2017.3917. View